HEALTH RESOURCE UTILIZATION (HRU) AND COSTS FOR METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH FIRST-LINE (1L) SYSTEMIC THERAPY IN THE UNITED STATES

被引：0
|
作者：
Mhatre, S. [1 ]
Lin, S. [1 ]
Surinach, A. [2 ]
Vohra, R. [1 ]
Satram-Hoang, S. [1 ]
Simpson, J. [1 ]
Wallen, H. [1 ]
Ogale, S. [1 ]
Gong, J. [3 ]
Pal, S. K. [3 ]
George, D. J. [4 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Genesis Res LLC, Hoboken, NJ USA
[3] City Hope Comprehens Canc Ctr, Duarte, CA USA
[4] Duke Univ Hosp, Durham, NC USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2332
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN256
引用
收藏
页码：A755 / A755
页数：1
相关论文
共 50 条
  • [1] Real-world (RW) outcomes in metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) in the United States
    Geynisman, D.
    Chan, P.
    Robert, N.
    Chen, L.
    Del Tejo, V.
    Rosenblatt, L. C.
    Huo, S.
    Doshi, G.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1216 - S1216
  • [2] Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States
    Klink, Andrew J.
    Chmielowski, Bartosz
    Feinberg, Bruce
    Ahsan, Sama
    Nero, Damion
    Liu, Frank Xiaoqing
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (08): : 869 - 877
  • [3] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Gallardo, Jorge
    Lesovoy, Vladmir
    Al-Shukri, Salman
    Stus, Viktor
    Bair, A. H.
    Rosbrook, Brad
    Bycott, Paul W.
    Tarazi, Jamal Christo
    Kim, Sinil
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [4] Understanding real world treatment patterns, healthcare resource utilization (HRU) and costs among metastatic renal cell carcinoma (mRCC) patients
    Copher, R.
    Byfield, S. Dacosta
    Buzinec, P.
    Korrer, S.
    Baig, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States
    van Boemmel-Wegmann, Sascha
    Brown, Joshua D.
    Diaby, Vakaramoko
    Huo, Jinhai
    Silver, Natalie
    Park, Haesuk
    JCO ONCOLOGY PRACTICE, 2022, 18 (01) : 80 - E174
  • [6] Influence of diabetes and congestive heart failure (CHF) on selection of first-line (1L) treatment for metastatic renal cell carcinoma (mRCC)
    Gong, J.
    George, D.
    Mhatre, S.
    Lin, S-W.
    Surinach, A.
    Wallen, H.
    Vohra, R.
    Simpson, J.
    Ogale, S.
    Pal, S. K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Evolution of circulating tumor DNA (ctDNA) profile from first-line (1L) to second-line (2L) therapy in metastatic renal cell carcinoma (mRCC).
    Pal, Sumanta K.
    Sonpavde, Guru
    Agarwal, Neeraj
    Vogelzang, Nicholas J.
    Srinivas, Sandy
    Haas, Naomi B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [8] REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION (HRU) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Bhanegaonkar, A.
    Gauthier, G.
    Kim, R.
    Vekeman, F.
    Dea, K.
    Robitaille, M. N.
    Moyneur, E.
    Liu, F. X.
    VALUE IN HEALTH, 2020, 23 : S84 - S84
  • [9] Treatment modification with sunitinib in first-line (1L) metastatic renal cell carcinoma (mRCC): An analysis of the STAR-TOR registry.
    Boegemann, Martin
    Hubbe, Marcus
    Thomaidou, Despina
    Blackburn, Stuart
    Bent-Ennakhil, Nawal
    Wood, Robert
    Bargo, Danielle
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [10] Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
    Shah, Neil J.
    Sura, Sneha
    Shinde, Reshma
    Shi, Junxin
    Perini, Rodolfo F.
    Puneet, Singhal
    Robert, Nicholas J.
    Vogelzang, Nicholas J.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345